Nautilus Biotechnology to Present at EuPA and AACR Meetings
• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA)
• Associate Director Greg Kapp, Ph.D., to present poster at American Association for Cancer Research (AACR) Annual Meeting
SEATTLE, April 04, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced presentations at the following leading scientific and medical conferences.
XIV Annual Congress of the European Proteomics Association (EuPA): Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus, is scheduled to present at EuPA, or the Proteomic Forum, in Leipzig, Germany on Wednesday, April 6, 2022 at 1:30 p.m. CET (4:30 a.m. PT / 7:30 a.m. ET). Dr. Mallick’s presentation titled “Development of a Novel, Single-Molecule Proteomics Analysis Platform” will be held during the Emerging Technologies symposium in Room Händel.
American Association for Cancer Research (AACR) Annual Meeting: Greg Kapp, Ph.D., Associate Director of Applications Development at Nautilus, will present a poster titled “Toward comprehensive, single-molecule proteomics: Protein identification by short-epitope mapping” on Wednesday, April 13, 2022 at 9:00 a.m. CT (7:00 a.m. PT / 10:00 a.m. ET) in New Orleans, LA. Dr. Kapp’s poster presentation will take place in Section 21 during Session PO.CH03.01 - Proteomics, Signaling Networks, and Biomarker Discovery. The embargoed abstract will be released on Friday, April 8, 2022 at 12:00 p.m. CT (10:00 a.m. PT / 1:00 p.m. ET) to registered meeting attendees.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations with respect to the suitability of the Nautilus product platform to investigate proteins and proteoforms; and expectations with respect to the functionality and performance of Nautilus’ product platform, its potential impact on pharmaceutical development and drug discovery. These statements are based on numerous assumptions concerning the development of Nautilus’ products and target markets and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in the Registration Statement on Form S-1 filed with the SEC as well as in our Annual Report on Form 10-K filed for the year ended December 31, 2021. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.